Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOST Switch trial of switching boosted protease inhibitor to fostemsavir in virologically suppressed adults with HIV-1
ISRCTN10901519Phase 4Completed
- Sponsor
- NEAT ID Foundation
- Start
- Feb 2024
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of fostemsavir in Human immunodeficiency virus infection type 1, sponsored by NEAT ID Foundation. Primary endpoint: Confirmed HIV viral load at or above 50 copies/mL at week 48. Started Feb 2024; status: completed.
02
Drugs
fostemsavir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on ISRCTN10901519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN10901519.